Acimmune Therapeutics is a clinical-stage biopharmaceutical company that develops therapeutic and diagnostic products for neurodegenerative diseases by targeting misfolded pathological proteins. The company operates two proprietary technology platforms—the Morphomer platform for small molecule therapeutics targeting protein misfolding diseases like Tau and alpha-synuclein, and the SupraAntigen platform for active immunotherapies against misfolded proteins—with a pipeline spanning Alzheimer's disease, Parkinson's disease, and other tauopathies. Since the company has no approved products or commercial sales, it finances operations through upfront payments and milestone payments from strategic partnerships with major pharmaceutical companies, royalties on licensed programs, and equity offerings.